Related Experiment Video
Updated: Apr 14, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Targeting mitosis-regulating genes in cisplatin-sensitive and -resistant melanoma cells: A live-cell RNAi screen
Holger Erfle1, K Pashayeva2,3, N Harder4
1BioQuant, Heidelberg University, Heidelberg, Germany. holger.erfle@bioquant.uni-heidelberg.de.
Abstract:
Chemoresistance in malignant melanoma remains an unresolved clinical issue. In the search for novel molecular targets, a live-cell high-content RNAi screen based on gene expression data was performed in cisplatin-sensitive and cisplatin-resistant MeWo melanoma cells, Mel-28 cells and a melanocyte cell line. Cells were exposed to 91 siRNAs and distinct nucleus-derived phenotypes such as cell division, cell death and migration phenotypes were detected by time-lapse microscopy over 60 h. Using this approach, cisplatin-sensitive and cisplatin-resistant melanoma cells were compared by automated image analysis and visual inspection. In cisplatin-sensitive MeWo melanoma cells, 14 genes were identified that showed distinct phenotype abnormalities after exposure to gene-specific siRNAs. In cisplatin-resistant MeWo cells, five genes were detected. Nine genes were detected whose knock-down led to differential nuclear phenotypes in cisplatin-sensitive and -resistant cells. In Mel-28 cells, nine genes were identified which induced nuclear phenotypes including all eight genes which were identified in cisplatin-resistant MeWo cells. An analogous RNAi screen on melanocytes revealed no detectable phenotype abnormalities after RNAi. Pathway analysis showed in cisplatin-sensitive MeWo cells and Mel-28 cells an enrichment of at least three genes in major mitotic pathways. We hereby show that siRNA screening may help to identify tumor-specific genes leading to phenotype abnormalities. These genes may serve as potential therapeutic targets in the treatment of melanoma.
Insights
Researchers identified novel genes associated with chemoresistance in melanoma using RNA interference (RNAi) screening. These identified genes may offer potential therapeutic targets for improving melanoma treatment outcomes.
Area of Science:
- Genetics and Molecular Biology
- Oncology
- Cell Biology
Background:
- Chemoresistance in malignant melanoma presents a significant clinical challenge.
- Identifying novel molecular targets is crucial for developing effective melanoma therapies.
Purpose of the Study:
- To identify genes associated with cisplatin sensitivity and resistance in melanoma cells.
- To discover potential tumor-specific therapeutic targets for melanoma treatment.
Main Methods:
- A live-cell, high-content RNA interference (RNAi) screen was conducted using cisplatin-sensitive and resistant melanoma cell lines (MeWo, Mel-28) and melanocytes.
- Cells were treated with 91 siRNAs, and nuclear phenotypes (cell division, death, migration) were monitored over 60 hours using time-lapse microscopy.
- Automated image analysis and visual inspection were employed to compare phenotypes between sensitive and resistant cells.
Main Results:
- 14 genes induced distinct phenotype abnormalities in cisplatin-sensitive MeWo cells; 5 genes in cisplatin-resistant MeWo cells.
- Nine genes showed differential nuclear phenotypes in sensitive versus resistant cells.
- RNAi screening in melanocytes did not reveal detectable phenotype abnormalities, suggesting tumor specificity.
Conclusions:
- RNA interference screening is a viable method for identifying tumor-specific genes linked to phenotype abnormalities in melanoma.
- The identified genes represent potential therapeutic targets for overcoming chemoresistance in malignant melanoma.
